Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its target price hoisted by Needham & Company LLC from $32.00 to $33.00 in a report released on Wednesday morning, Marketbeat.com reports. They currently have a buy rating on the stock.
Several other research firms also recently commented on DAWN. Piper Sandler reiterated an overweight rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. HC Wainwright restated a buy rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, August 1st. Bank of America upgraded shares of Day One Biopharmaceuticals from an underperform rating to a buy rating and upped their price target for the company from $11.00 to $24.00 in a research note on Thursday, August 1st. Wedbush restated an outperform rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an overweight rating on the stock in a research note on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals has a consensus rating of Moderate Buy and a consensus price target of $35.71.
View Our Latest Analysis on Day One Biopharmaceuticals
Day One Biopharmaceuticals Price Performance
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.70. The company had revenue of $8.19 million during the quarter, compared to analyst estimates of $0.90 million. As a group, equities research analysts expect that Day One Biopharmaceuticals will post -1.68 earnings per share for the current year.
Insiders Place Their Bets
In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,232 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $31,248.00. Following the sale, the insider now directly owns 1,127,535 shares in the company, valued at $15,785,490. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the transaction, the insider now owns 1,097,535 shares of the company’s stock, valued at approximately $15,606,947.70. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Samuel C. Blackman sold 2,232 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $31,248.00. Following the completion of the transaction, the insider now directly owns 1,127,535 shares of the company’s stock, valued at $15,785,490. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,748 shares of company stock worth $1,009,272 over the last ninety days. Corporate insiders own 8.40% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in DAWN. Deerfield Management Company L.P. Series C lifted its holdings in shares of Day One Biopharmaceuticals by 65.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock worth $40,281,000 after acquiring an additional 1,157,825 shares during the last quarter. Estuary Capital Management LP boosted its position in Day One Biopharmaceuticals by 82.5% during the 1st quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock worth $26,616,000 after buying an additional 728,240 shares during the period. Ally Bridge Group NY LLC acquired a new stake in Day One Biopharmaceuticals during the 2nd quarter worth approximately $7,387,000. Goldman Sachs Group Inc. boosted its position in Day One Biopharmaceuticals by 28.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock worth $30,935,000 after buying an additional 472,654 shares during the period. Finally, Point72 Asset Management L.P. acquired a new stake in Day One Biopharmaceuticals during the 2nd quarter worth approximately $6,480,000. Institutional investors own 87.95% of the company’s stock.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
See Also
- Five stocks we like better than Day One Biopharmaceuticals
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Stock Average Calculator
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.